Abstract
Importance Antibiotic resistance is a growing concern due to overuse and misuse of antibiotics. Quantitative assessments of the risk of future resistance caused by different antibiotics are limited, although essential for improved guidelines for responsible antibiotic prescription.
Objective To employ instrumental variable (IV) analysis using reported penicillin allergy to estimate the causal effects of prior penicillin use on the development of antibiotic resistance.
Design Retrospective cohort study spanning from 2013 to 2022, with a follow-up period extending to 12 months.
Setting Primary Care
Participants The study analyzed 36,351 adults who underwent an AMR test prompted by a positive urine culture, representing 2.5% of the initial cohort of eligible adults who purchased antibiotics in primary care. Exclusion criteria included recent antibiotic use, hospitalization, nursing home residence, being homebound, or purchasing multiple antibiotic types.
Main Outcome(s) and Measure(s) Binary results of antibiotic susceptibility tests at follow-up times of up to 90, 180, 270, and 365 days. We focused on resistance to ampicillin, amoxicillin/clavulanic acid, piperacillin/tazobactam, and ciprofloxacin, using gentamicin as a negative control outcome.
Results The rate difference (RD) of resistance due to previous penicillin use compared to other antibiotics within 12 months was 15.2% (95% CI: 9.8%, 21.4%) for amoxicillin/clavulanic acid, 11.8% (95% CI: 5.5%, 20.3%) for ampicillin, and 1.0% (95% CI: 0.3%, 1.9%) for piperacillin/tazobactam, with NNH values of 6.6, 8.5, and 98, respectively. Gentamicin, used as a negative control, showed no effect. Direct comparison of penicillins and quinolones within 180 days post-exposure revealed that penicillins increased resistance to amoxicillin/clavulanic acid by an RD of 14.9% (95% CI: 2.9%, 24.6%; NNH: 6.7), while quinolones increased resistance to ciprofloxacin by 34.7% (95% CI: 25.3%, 45.9%; NNH: 2.9).
Conclusions and Relevance The study provides causal estimates of how prior use of penicillins and quinolones in outpatient settings impacts future antibiotic resistance, with implications for treatment guidelines and clinical practice. Additionally, it introduces a novel methodological approach to quantify antibiotic-induced resistance, which can be applied to other antibiotic groups known to cause allergic reactions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Israel Science Foundation (ISF 1286/21)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received approval from the Institutional Review Board (IRB) of Maccabi Healthcare Services. Given the retrospective nature of the study, the IRB waived the requirement for informed consent since all identifying participant information had been removed before the analysis
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
According to the Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified community-level data should be referred to KSM, Maccabi Healthcare Services Research and Innovation Center.
